Carrie K. Jones

发表

Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core.

Julie L. Engers, Andrew S. Felts, Anna L. Blobaum, 2017, ACS medicinal chemistry letters.

Sexual Dimorphism in Stress‐induced Hyperthermia in SNAP25Δ3 mice, a mouse model with disabled Gβγ regulation of the exocytotic fusion apparatus

H. Hamm, C. Jones, Zack Zurawski, 2020, The European journal of neuroscience.

Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.

Julie L. Engers, Andrew S. Felts, Anna L. Blobaum, 2018, ACS medicinal chemistry letters.

Classics in Chemical Neuroscience: Xanomeline.

C. Lindsley, Carrie K. Jones, Aaron M. Bender, 2017, ACS chemical neuroscience.

Modulation of arousal and sleep/wake architecture by M1 PAM VU0453595 across young and aged rodents and nonhuman primates

Anna L. Blobaum, M. Nader, P. Newhouse, 2020, Neuropsychopharmacology.

The Role of Estrogen in Brain and Cognitive Aging

P. Newhouse, C. Jones, Jason K Russell, 2019, Neurotherapeutics.

Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice

Z. Xiang, C. Lindsley, P. Conn, 2015, Proceedings of the National Academy of Sciences.

Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats

A. Deutch, A. Levey, R. Kessler, 2008, The Journal of Neuroscience.

Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

C. Lindsley, P. Conn, C. Jones, 2009, Trends in pharmacological sciences.

Muscarinic receptor pharmacology and circuitry for the modulation of cognition.

N. Byun, M. Bubser, Michael Bubser, 2012, Handbook of experimental pharmacology.

Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling.

P. Conn, C. Jones, Daniel J. Foster, 2012, Discovery medicine.

Novel Allosteric Agonists of M1 Muscarinic Acetylcholine Receptors Induce Brain Region-Specific Responses That Correspond with Behavioral Effects in Animal Models

M. Foster Olive, J. Scott Daniels, P. Jeffrey Conn, 2012, The Journal of Neuroscience.

Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.

S. Jadhav, J. Meiler, Z. Xiang, 2010, ACS chemical neuroscience.

Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas

Kirk W. Johnson, K. Perry, G. Nomikos, 2008, Neuropharmacology.

Phosphodiesterase 10 A Regulates Alcohol and Saccharin Self-Administration in Rats

Robert L Barry, John C Gore, P Jeffrey Conn, 2014 .

Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators

Anna L. Blobaum, J. Cheer, C. Lindsley, 2018, Molecular Psychiatry.

Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents

Kari A. Johnson, K. Gregory, J. Bartolomé-Nebreda, 2015, Neuron.

Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.

S. Jadhav, J. Meiler, Z. Xiang, 2010, ACS chemical neuroscience.

Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor

J. Wess, Z. Xiang, C. Lindsley, 2017, Neuron.

Acetylcholine Muscarinic M4 Receptors as a Therapeutic Target for Alcohol Use Disorder: Converging Evidence From Humans and Rodents

Alice E. Berizzi, C. Langmead, A. Christopoulos, 2020, Biological Psychiatry.

Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release

M. J. Uddin, J. Wess, Z. Xiang, 2016, Neuron.

Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.

Andrew S. Felts, Brittney S. Bates, Anna L. Blobaum, 2013, Bioorganic & medicinal chemistry letters.

Partial mGlu5 Negative Allosteric Modulator M-5MPEP Demonstrates Antidepressant-Like Effects on Sleep Without Affecting Cognition or Quantitative EEG

C. Lindsley, R. Gould, C. Jones, 2021, Frontiers in Neuroscience.

Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation

Andrew S. Felts, Brittney S. Bates, Anna L. Blobaum, 2017, Journal of medicinal chemistry.

(3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addiction.

Brittney S. Bates, S. Jadhav, C. Lindsley, 2011, ACS chemical neuroscience.

3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure in rats.

Andrew S. Felts, S. Jadhav, C. Lindsley, 2010, Bioorganic & medicinal chemistry letters.

Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.

Andrew S. Felts, Anna L. Blobaum, C. Lindsley, 2019, Bioorganic & medicinal chemistry letters.

N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents.

Andrew S. Felts, Anna L. Blobaum, C. Lindsley, 2016, Bioorganic & medicinal chemistry letters.

Partial mGlu5 Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects

Andrew S. Felts, C. Lindsley, P. Conn, 2016, Neuropsychopharmacology.

Chapter 71 – Negative Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 for the Treatment of Cocaine Use Disorder

Andrew S. Felts, R. Gould, C. Jones, 2017 .

Development and kilogram-scale synthesis of mGlu5 negative allosteric modulator VU0424238 (auglurant)

Anna L. Blobaum, C. Lindsley, P. Conn, 2017 .

mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome.

C. Lindsley, P. Conn, S. Stauffer, 2016, Human molecular genetics.

Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.

Julie L. Engers, Anna L. Blobaum, C. Lindsley, 2015, Journal of medicinal chemistry.

Chemical Modulation of Mutant mGlu1 Receptors Derived from Deleterious GRM1 Mutations Found in Schizophrenics

C. Lindsley, C. Hopkins, Hyekyung P. Cho, 2014, ACS chemical biology.

Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines.

C. Lindsley, P. Conn, Alice L. Rodriguez, 2009, Journal of medicinal chemistry.

Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012.

Bruce J. Melancon, D. Sheffler, C. Lindsley, 2012, Bioorganic & medicinal chemistry letters.

Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe.

D. Sheffler, C. Lindsley, Hyekyung P. Cho, 2011, Bioorganic & medicinal chemistry letters.

Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia

Carrie K. Jones, N. Byun, M. Bubser, 2012, Neuropsychopharmacology.

Synthesis and Structure–Activity Relationships of Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor

J. P. Kennedy, C. Lindsley, P. Conn, 2009, ChemMedChem.

Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins.

S. Jadhav, C. Lindsley, Joy E. Marlo, 2009, Journal of medicinal chemistry.

Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats

S. Jadhav, J. P. Kennedy, C. Lindsley, 2008, Journal of Pharmacology and Experimental Therapeutics.

Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties.

J. P. Kennedy, C. Lindsley, P. Conn, 2008, Bioorganic & medicinal chemistry letters.

Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.

Craig W Lindsley, C. Lindsley, Carrie K Jones, 2009, Trends in pharmacological sciences.

The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease

Kari A. Johnson, R. Baldwin, P. Conn, 2013, Neuropharmacology.

Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4

Kari A. Johnson, Z. Xiang, C. Lindsley, 2008, Molecular Pharmacology.

Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs.

Julie L. Engers, Anna L. Blobaum, C. Lindsley, 2017, ACS chemical neuroscience.

A Novel M1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity.

S. P. Moran, Anna L. Blobaum, C. Lindsley, 2018, ACS chemical neuroscience.

Continued optimization of the M5 NAM ML375: Discovery of VU6008667, an M5 NAM with high CNS penetration and a desired short half-life in rat for addiction studies.

C. Lindsley, P. Conn, Kellie D. Nance, 2017, Bioorganic & medicinal chemistry letters.

Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes.

Jens Meiler, P Jeffrey Conn, Craig W Lindsley, 2016, Bioorganic & medicinal chemistry letters.

A Novel Selective Muscarinic Acetylcholine Receptor Subtype 1 Antagonist Reduces Seizures without Impairing Hippocampus-Dependent Learning

S. Jadhav, D. Sheffler, Z. Xiang, 2009, Molecular Pharmacology.

Biphenyl-indanone A, a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like Effects in Mice

P. Conn, Y. Nong, T. de Paulis, 2006, Journal of Pharmacology and Experimental Therapeutics.

Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.

P. Conn, M. Noetzel, C. Jones, 2012, Discovery medicine.

Microsoft Word-26751875-file00

Kari A. Johnson, Days, C. Lindsley, 2008 .

New therapeutic frontiers for metabotropic glutamate receptors.

P. Conn, C. Niswender, C. Jones, 2005, Current topics in medicinal chemistry.

VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy

Brittney S. Bates, K. Gregory, Z. Xiang, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity

P Jeffrey Conn, Craig W Lindsley, Colleen M Niswender, 2010, Molecular Pharmacology.

Anatomical localization of Cav3.1 calcium channels and electrophysiological effects of T-type calcium channel blockade in the motor thalamus of MPTP-treated monkeys.

I. Hamada, T. Wichmann, Y. Smith, 2016, Journal of neurophysiology.

The antipsychotic potential of muscarinic allosteric modulation.

C. Lindsley, C. Hopkins, E. Lebois, 2010, Drug news & perspectives.

Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).

J. Bartolomé-Nebreda, M. Martín-Martín, Carlos M Martínez-Viturro, 2015, Bioorganic & medicinal chemistry letters.

Functional Impact of Allosteric Agonist Activity of Selective Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 in Regulating Central Nervous System Function

H. Lavreysen, Z. Xiang, C. Lindsley, 2012, Molecular Pharmacology.

A rodent model of traumatic stress induces lasting sleep and quantitative electroencephalographic disturbances.

C. Lindsley, M. Ivarsson, P. Conn, 2015, ACS chemical neuroscience.

OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior

Kenji F. Tanaka, H. Moore, J. Veenstra-VanderWeele, 2017, Proceedings of the National Academy of Sciences.